TRIM24 promotes stemness and invasiveness of glioblastoma cells via activating Sox2 expression
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Glioblastoma stem cells (GSCs) are a subpopulation of glioblastoma (GBM) cells that are critical for tumor invasion and treatment resistance. However, little is known about the function and mechanism of tripartite motif-containing 24 (TRIM24) in GSCs.
METHODS: Immunofluorescence, flow cytometry, and western blot analyses were used to evaluate TRIM24 and cluster of differentiation (CD)133 expression profiles in GBM surgical specimens and GSC tumorspheres. Different TRIM24 expression levels in patients' tumors, as measured by both immunohistochemistry and western blot, were related to their corresponding MRI data. Wound healing, Matrigel invasion, and xenograft immunohistochemistry were conducted to determine GBM cell invasion.
RESULTS: We identified that TRIM24 was coexpressed with CD133 and Nestin in GBM tissues and tumorsphere cells. Limiting dilution assays and xenotransplantation experiments illustrated that knockdown of TRIM24 expression reduced GSC self-renewal capacity and invasive growth. TRIM24 expression levels were positively associated with the volumes of peritumoral T2 weighted image abnormality. Rescue experiments indicated TRIM24 participation in GBM infiltrative dissemination. Chromatin immunoprecipitation, reporter gene assay, PCR, western blot, and immunohistochemistry demonstrated that TRIM24 activated the expression of the pluripotency transcription factor sex determining region Y-box 2 (Sox2) to regulate GBM stemness and invasion in vitro and in vivo. Finally, the close relationship between TRIM24 and Sox2 was validated by testing samples enrolled in our study and exploring external databases.
CONCLUSIONS: Our findings uncover essential roles of the TRIM24-Sox2 axis in GBM stemness and invasiveness, suggesting TRIM24 as a potential target for effective GBM management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Neuro-oncology - 22(2020), 12 vom: 18. Dez., Seite 1797-1808 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Lu-Hua [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carrier Proteins |
|---|
| Anmerkungen: |
Date Completed 28.04.2021 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/neuonc/noaa138 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310723744 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310723744 | ||
| 003 | DE-627 | ||
| 005 | 20231225140716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/neuonc/noaa138 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310723744 | ||
| 035 | |a (NLM)32492707 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Lu-Hua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TRIM24 promotes stemness and invasiveness of glioblastoma cells via activating Sox2 expression |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Glioblastoma stem cells (GSCs) are a subpopulation of glioblastoma (GBM) cells that are critical for tumor invasion and treatment resistance. However, little is known about the function and mechanism of tripartite motif-containing 24 (TRIM24) in GSCs | ||
| 520 | |a METHODS: Immunofluorescence, flow cytometry, and western blot analyses were used to evaluate TRIM24 and cluster of differentiation (CD)133 expression profiles in GBM surgical specimens and GSC tumorspheres. Different TRIM24 expression levels in patients' tumors, as measured by both immunohistochemistry and western blot, were related to their corresponding MRI data. Wound healing, Matrigel invasion, and xenograft immunohistochemistry were conducted to determine GBM cell invasion | ||
| 520 | |a RESULTS: We identified that TRIM24 was coexpressed with CD133 and Nestin in GBM tissues and tumorsphere cells. Limiting dilution assays and xenotransplantation experiments illustrated that knockdown of TRIM24 expression reduced GSC self-renewal capacity and invasive growth. TRIM24 expression levels were positively associated with the volumes of peritumoral T2 weighted image abnormality. Rescue experiments indicated TRIM24 participation in GBM infiltrative dissemination. Chromatin immunoprecipitation, reporter gene assay, PCR, western blot, and immunohistochemistry demonstrated that TRIM24 activated the expression of the pluripotency transcription factor sex determining region Y-box 2 (Sox2) to regulate GBM stemness and invasion in vitro and in vivo. Finally, the close relationship between TRIM24 and Sox2 was validated by testing samples enrolled in our study and exploring external databases | ||
| 520 | |a CONCLUSIONS: Our findings uncover essential roles of the TRIM24-Sox2 axis in GBM stemness and invasiveness, suggesting TRIM24 as a potential target for effective GBM management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Sox2 | |
| 650 | 4 | |a TRIM24 | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a invasion | |
| 650 | 4 | |a stemness | |
| 650 | 7 | |a Carrier Proteins |2 NLM | |
| 650 | 7 | |a SOX2 protein, human |2 NLM | |
| 650 | 7 | |a SOXB1 Transcription Factors |2 NLM | |
| 650 | 7 | |a TRIM24 protein, human |2 NLM | |
| 700 | 1 | |a Yin, Yi-Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hong-Zun |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Shi-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jia-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Wen-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Guo-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xin-Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Dong-Gang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuro-oncology |d 1999 |g 22(2020), 12 vom: 18. Dez., Seite 1797-1808 |w (DE-627)NLM111754321 |x 1523-5866 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:12 |g day:18 |g month:12 |g pages:1797-1808 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/neuonc/noaa138 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 12 |b 18 |c 12 |h 1797-1808 | ||